About Diamedica
DiaMedica is a biopharmaceutical company focused on developing novel therapeutic products that will dramatically improve the lives of people with Type 1 diabetes, Type 2 diabetes and other large-scale diseases. The Company's product portfolio protects and proliferates specific cells in specific organs. In addition, DiaMedica's products have demonstrated an ability to dramatically improve glucose infusion rates.
DiaMedica is a publicly traded company, listed on the Toronto Stock Exchange Venture under the symbol DMA.
Recent Headlines
Dec 19th, 2011
DiaMedica’s DM-204 for Type 2 Diabetes Successfully Humanized
WINNIPEG, Manitoba, Canada – December 19, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce the successful humanization of its monoclonal antibody (mAb), DM-204, for Type 2 diabetes and diabetic related complications of hypertension (high blood pressure) and cholesterol.
>> Read More...Dec 5th, 2011
DiaMedica’s DM-199 for Type 1 Diabetes Significantly Delays Autoimmune Attack and Demonstrates a Dramatic Increase in C-Peptide Levels
WINNIPEG, Manitoba, Canada – December 5th, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce new compelling Type 1 diabetes data. An in vivo study with the chronic administration of DM-199 significantly delayed the autoimmune attack, preserved beta cell mass and demonstrated a 12-fold increase in circulating C-peptide levels in the non-obese diabetic (NOD...
>> Read More...Dec 1th, 2011
DiaMedica’s DM-204 for Type 2 Diabetes Significantly Lowers Blood Glucose, Blood Pressure and Cholesterol Levels
WINNIPEG, Manitoba, Canada – December 1st, 2011 – DiaMedica Inc. (TSX-V: DMA) is pleased to announce the presentation of new compelling Type 2 diabetes data from studies of DM-204 at the Windhover Therapeutic Area Partnership Conference in Boston, MA, USA.
In an independently conducted study, chronic administration of DM-204 prevented disease progression...
>> Read More...